News, Publications & Insights

Explore the latest news and publications, innovation milestones, and drug-device insights from PARI and our pharmaceutical partners leveraging eFlow® Technology.

PARI Partner Project News

Partner Project News

Enterprise Therapeutics achieves primary efficacy outcome in Phase 2 clinical trial for cystic fibrosis with novel inhaled ENaC blocker ETD001

PARI Publication

PARI Publication

A Novel Human Factors Approach for a New Platform-Based, Breath-Triggered Nebuliser

Published

September 30, 2026

Category

PARI Publications

Effect of Nebulizer Breath-Guiding on Breathing Patterns and Lung Deposition

Published

September 21, 2026

Category

Publications

Nebulized nintedanib (AP02) for idiopathic pulmonary fibrosis demonstrates favorable safety and lung lining fluid exposures: results from two phase I safety, tolerability, and pharmacokinetics studies

Published

September 21, 2026

Category

Partner News

FDA Grants Priority Review to Insmed's sNDA for ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of MAC Lung Disease With PDUFA Target Action Date Set for January 28, 2027

Published

September 9, 2026

Category

Publications

Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial

Published

September 9, 2026

Category

PARI Publications

Impact of Digital Breath-Guiding on Inhalation Technique and Drug Deposition

Contact us

eFlow-partneringpari.com

Two smiling men in a blue circle. The central man wears glasses and a light blue shirt. The man on the left has a beard and a blue patterned shirt.

PARI Business Development Team